SKiT (abacavir to tenofovir)

This trial is no longer enrolling. This may mean the trial is fully enrolled, or that enrolment in the trial has been halted or suspended. You cannot enrol in this trial.

About this trial

The purpose of this study is to evaluate cardiovascular function in HIV-infected adults before and after switching their HIV treatment from Kivexa to Truvada (or from Abacavir to Tenofovir).
The theory being tested is that markers of cardiovascular function (as measured by applanation tonometry*) will improve in patients switching from ABC-3TC to TDF-FTC.

Background information

*Tonometry is a procedure which measures the pressure inside the eyes. An applanation tonometer is an instrument for determining ocular tension by application of a small flat disk to the cornea.

Official title:

Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir) in people with Human Immunodeficiency Virus (HIV).

What is this trial studying?

se_management – tenofovir, Truvada

Start date:

actual start date: 23/09/2008 (This may be the proposed or expected start date for trials which have not yet started.)

How many participants will this trial enrol?

20 (The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.)

How long is this trial planned to go for?

Participants in this trial will be asked to follow the trial protocol for 24 weeks.

Links to further information:

• http://www.anzctr.org.au/trial_view.aspx?ID=83364

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

• At least 18 years old
• Currently taking HIV treatments
• Viral load below 50 copies/ml
• Has been on stable antiretroviral therapy including abacavir (ABC) or ABC-3TC for at least six months.

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

Before making the decision to participate in any clinical research, visit the NAPWA website for background information on participating in clinical research.

Contact NAPWA if you have any questions or comments about this trial.